The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEYNOTE-177: First-line, open-label, randomized, phase III study of pembrolizumab (MK-3475) versus investigator-choice chemotherapy for mismatch repair deficient or microsatellite instability-high metastatic colorectal carcinoma.
 
Luis A. Diaz
No Relationships to Disclose
 
Dung T. Le
Research Funding - Aduro Biotech; Bristol-Myers Squibb; Merck
 
Takayuki Yoshino
No Relationships to Disclose
 
Thierry Andre
No Relationships to Disclose
 
Johanna C. Bendell
No Relationships to Disclose
 
Yinghua Zhang
No Relationships to Disclose
 
Baohoang Lam
No Relationships to Disclose
 
Minori Koshiji
No Relationships to Disclose
 
Dirk Jäger
No Relationships to Disclose